Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, announced the launch of Nepexto®, its biosimilar to the reference product Enbrel® (Etanercept), in Australia.
Nepexto® will be promoted in Australia through Biocon Biologics’ local partner, Generic Health, a leading supplier of generic, injectable, and over-the-counter medicines. This launch is aimed at improving access for patients in Australia suffering from autoimmune conditions.
Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is widely used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.
Nepexto® had already received EU marketing authorization in 2020 and has since gained broad adoption across Europe. After acquiring and vertically integrating its global biosimilars business in 2022, Biocon Biologics has been strategically expanding Nepexto® into new markets as part of its strengthened immunology portfolio.
The company stated that this milestone underscores its ongoing efforts to enhance global access to high-quality, affordable biologics.
Nepexto® is a registered trademark of Biosimilars New Co Limited, a Biocon Biologics company.
